Please assess the completion status of the following clinical trial:

Trial Title: Rapid Antidepressant Effects of Yohimbine in Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Male or female subjects, 18 to 65 years of age.~Female subjects of childbearing potential must be using a medically accepted means of contraception.~Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document.~Subjects must fulfill DSM-IV criteria for Major Depression, based on clinical assessment and confirmed by a structured diagnostic interview, SCID-P.~Subjects must have an initial score of at least 18 on the 21-item HDRS at screen and at baseline of TSD and Study Phase II.~Subjects with a greater than 25% decrease in the 21-item HDRS total scores between screen and baseline of TSD will be dropped from the study.~EXCLUSION CRITERIA:~Subjects with documented uncontrolled hypertension in the 30 days prior to Study Period I, or have a systolic blood pressure greater than or equal to 140 and/or diastolic blood pressure greater than or equal to 90 on 3 or more readings during the drug-free period.~Apnea/hypopnea index is greater than 15 episodes per minute.~Presence of psychotic features or a diagnosis of Schizophrenia or any other psychotic disorder as defined in the DSM-IV.~Subjects with current DSM-IV diagnosis of generalized anxiety disorder, panic disorder, or posttraumatic stress disorder.~Subjects with a history of DSM-IV drug or alcohol dependency or abuse (including for nicotine) within the preceding 3 months.~Female subjects who are either pregnant or nursing.~Serious, unstable illnesses including hepatic, renal gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.~DSM-IV diagnosis of primary sleep disorder.~Subjects with uncorrected hypothyroidism or hyperthyroidism.~Subjects with one or more seizures without a clear and resolved etiology.~Documented history of hypersensitivity or intolerance to yohimbine.~Treatment with a reversible MAOI within 4 weeks prior to Study Phase II.~Treatment with fluoxetine within 3 weeks prior to Study Phase II.~Treatment with any other concomitant medication not allowed 7 days prior to Study Phase II.~Treatment with clozapine or ECT within 3 months prior to Study Phase I.~Judged clinically to be at serious suicide risk.~Previous nonresponse to total sleep deprivation treatment.~STUDY PHASE II:~INCLUSION CRITERIA~Same as above plus:~Response to total sleep deprivation (40% decrease in the HAM-D6) followed by:~Depressive relapse (score of at least 18 on the 21-item HDRS and no longer meets response criteria) prior to Study Period II.~EXCLUSION CRITERIA:~YMRS total score of greater than or equal to 12 within 24 hours of yohimbine administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Yohimbine then Placebo (Type: EXPERIMENTAL): Participants are randomized to receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep. After 8 days they receive placebo administered over 3 minutes during REM sleep.
- Placebo then Yohimbine (Type: EXPERIMENTAL): Participants are randomized to receive placebo administered over 3 minutes during REM sleep. After 8 days they receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.

Based on this trial design, predict the completion outcome and termination type (if applicable).